Speculation Mounts Over Chinese Interest In Ethypharm
This article was originally published in PharmAsia News
Executive Summary
French firm Ethypharm’s portfolio in CNS and pain management is apparently attracting interest from Chinese and other pharma groups in a potential strategic acquisition, with Luye Pharma and Mundipharma emerging as possible bidders given their interest in M&A as a route to business expansion.